Antigenic proteins of Borrelia burgdorferi |
| It is an object of the present invention to provide a means for detecting mammals previously or ... |
|
Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90 |
| We claim: 1. An isolated DNA molecule consisting of a nucleotide sequence as shown in FIG. 3 for ACA... |
|
Isolation and use of solid tumor stem cells |
| The invention claimed is: 1. A method for determining the capability of a test compound to inhibit ... |
|
Hair analysis method |
| OF THE INVENTION In accordance with the present invention, a method is provided that permits the ... |
|
Method for retarding or precluding Alzheimer's dementia |
| OF THE INVENTION The markers which are targeted according to the method of the invention are those ... |
|
Streptococcus pneumoniae polynucleotides and sequences |
| OF ILLUSTRATIVE EMBODIMENTS The present invention is based on the sequencing of fragments of the S... |
|
Protection against dental caries |
| I claim: 1. A process for producing an antigen preparation, for use in the reduction or prevention ... |
|
High molecular weight polymer-based prodrugs |
| In one aspect of the invention, compositions of formula (I) are provided: ##STR2## wherein: D is a ... |
|
|
Vaccine against Gram-negative bacterial infections
| Details |
Inventors: Bhattacharjee, Apurba; Cross, Alan; Sadoff, Jerald; Zollinger, Wendell;
Assignee: United States of America as represented by the Secretary of the Army (Washington, DC)
Primary Examiner: Devi; S.
Assistant Examiner:
Attorney, Agent or Firm: Arwine; Elizabeth, Harris; Charles H., Moran; John Francis
A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine. |
|
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS According to the present invention, a non-covalent, polyvalent complex between purified, detoxified LPS ("DLPS") derived from E. coli and purified outer membrane protein derived from N. meningitidis is provided which, when injected into a host subject, actively immunizes the host subject against Gram-negative bacteria and LPS-mediated pathology. Post-immune serum or plasma from the host subject, or specific polyclonal antibody purified from these fluids, can be administered to a second subject, passively immunizing the second subject against infection by Gram-negative bacteria and LPS-induced pathology. The preferred strain of E. coli from which to prepare purified and detoxified LPS endotoxin is an E. coli J5 (Rc chemotype) strain. Native J5 LPS may be purchased from List Biological Labs, Inc. , Campbell, Calif. For purification purposes it is preferred that the LPS preparation contain less than about 1% protein and less than about 1% nucleic acid. By "purified E. coli LPS" is meant LPS suitable for use in the invention vaccine prepared by sonicating native LPS in an alkaline solution, heating the solution at 65° C. , neutralizing the cooled solution to pH 7. 0, removing released fatty acids and remaining native LPS by Sephadex G-50 chromatography, and collecting the purified, detoxified DLPS. As determined in a standard rabbit pyrogenicity test, this method reduces the pyrogenicity of LPS preparations, and thus are also referred to as DLPS. An embodiment of this procedure is described in Example 1 below. A preferred strain of meningococcus is N. meningitidis group B. The outer membrane protein therefrom (hereinafter "GBOMP") is prepared as described in Zollinger et al. , J. Clin. Invest. 63:836 (1079), and U. S. Pat. No. 4,707,543 (1987), the contents of which are incorporated herein by reference. Briefly, meningococcal group B cells are warmed to about 55 to 60° C. for a brief period, and disrupted in a shearing device such as OMNIMIX, sold by DuPont Instruments (Newtown, Conn
|
|